John P. Perentesis, MD, FAAP
Title
Director, Oncology Program
Appointment
Professor of Pediatrics
Email
john.perentesis@cchmc.org
Phone
513-636-8241
Fax
513-636-3549
Bio
Dr. Perentesis received his medical degree from the University of Michigan and pursued pediatric and hematology / oncology training at the University of Minnesota Medical School. After completion of his postdoctoral training, he was a member of the faculty of the University of Minnesota Cancer Center and led the Pediatric Advanced Therapies Program. He has substantial experience in pediatric developmental therapeutics, leading laboratory programs in the development of recombinant therapeutics and pharmacogenetics, and in the development and execution of Phase I & II pediatric anticancer drug clinical research studies. His laboratory has developed novel anticancer drugs and discovered genes important in the growth of normal and malignant cells. He is also member of the Steering Committee for the new national NIH-funded Pediatric Phase I / Pilot Consortium.
Credentials
MD: University of Michigan, Ann Arbor, MI, 1980.
Residency: Pediatrics, University of Minnesota Medical School, Minneapolis, MN, 1983.
Fellowship: Hematology / Oncology / Bone Marrow Transplantation, University of Minnesota Medical School, Minneapolis, MN, 1986.
Postdoctoral: Biochemistry and Oncology Research Postdoctoral (NIH Physician Scientist), University of Minnesota Medical School, Minneapolis, MN, 1986.
Certification: Pediatrics, 1989; Hematology / Oncology, 1990.
Awards and Honors
- Best Doctors in America, 2008
- Awarded "2005 Best Doctors"
- Awarded "2004 Best Doctors"
- William Branstrom Freshman Prize
- James B. Angell Scholar
- Horace H. Rackham Scholarship
- American Cancer Society Clinical Fellowship
- University of Minnesota Children's Foundation Faculty Scholar Award
- University of Minnesota Pew Scholars Award Nominee
- National Institutes of Health NIAID Physician Scientist Award
Research
Recombinant cancer therapeutics and molecular mechanisms for drug action
- Novel Gene & Anticancer Drug Discovery: Translational Elongation Factor 2 Genes: S. cerevisiae (Genbank M59369 and M59370)
- DTctGMCSF: Recombinant granulocyte-macrophage colony stimulating factor receptor – targeted diphtheria fusion toxin anti-leukemia drug (Blood, 82:384a, 1993)
Research Grants and Contracts
RO1 CA11178: 12/04-11/09 National Institute of Health, Molecular Studies of Down Syndrome Leukemia; PI
U10 CA07306: 01/03-12/08: National Institutes of Health - Children's Oncology Group (COG) Multi-Institution Clinical Trials Group; PI-CCHMC
U10 CA07306: 01/03-12/08: National Institutes of Health - Children's Oncology Group (COG) Multi-Institution Clinical Trials Group; Acute Myeloid Leukemia – Phase I Clinical Trial PI
U01 CA097452: 01/03-12/08: National Institutes of Health – Pediatric Phase I / Pilot Consortium; Steering Committee Member and PI-CCHMC
R01 ES07819: 4/00-3/05: National Institutes of Health: New Advances in Neuroblastoma Therapy (NANT) Consortium; PI-CCHMC
R01 CA76326: 1/1/02-12/31/07: National Institutes of Health Host Factors and Etiology of Leukemia; Co-Investigator
Publications, Most Recent
Connect to John Perentesis' publications on PubMed
Aplenc, R., Alonzo, T. A., Gerbing, R. B., Smith, F.O., Meshinchi, S., Ross, J.A., Perentesis, J., Woods, W.G., Lange, B. J., Davies, S. M. 2006. Ethnicity and survival in childhood acute myeloid leukemia: A report from the Children's Oncology Group. Blood, 108(1):74-80, 2006..
Mo J. , Lampkin B., Perentesis J., Poole L., Bao L. 2006 Translocation (8;18;16)(p11:q21; p13) a new variant of t(8;16)(p11; p13) in acute monoblastic leukemia: Case report and review of the literature. Cancer Genetics and Cytogenetics, 165(1): 75-78, 2006.
Mehta PA, Alonzo TA, Gerbing RB, Elliott JS, Wilke TA, Kennedy RJ, Ross JA, Perentesis JP, Lange BJ, Davies SM. XPD Lys751gln polymorphism: Etiology and outcome of childhood acute myeloid leukemia. A Children's Oncology Group report. Blood, 107(1): 39-45, 2006.
Fraser CJ, Weigel BJ, Perentesis JP, Dusenbery KE, Defor TE, Baker KS, Verneris MR. Autologous stem cell transplantation for high-risk Ewing's sarcoma and other pediatric solid tumors. Bone Marrow Transplant, 37(2): 175-81, 2006.
Aragani, P., Lae, M., Hutchinson, B., Reuter, V., Collins, M.H., Perentesis, J.P., Tomaszewski J.E., Brooks, J.S.J., Acs, G., Bridge, J.A., Vargas, S.O., Davis, I.J., Fisher, D.E., Ladanyi, M. Renal Carcinomas With the t(6;11)(p21;q12), Clinicopathologic Features and Demonstration of the Specific Alpha-TFEB Gene Fusion by Immunohistochemistry, RT-PCR, and DNA PCR. American Journal Pathology, 29(2): 230-240, 2005.
Shu, XO, Perentesis, J.P., Wen, W., Buckley, J.D., Boyle, E., Ross, J.A., Robison L.L.: Parental exposure to medications and hydrocarbons and ras mutations in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. Cancer Epidemiol Biomarkers Prev. 13:1230-35, 2004.
Mertens, A.C., Mitby, P.A., Radloff, G., Jones, I.M., Perentesis, J., Kiffmeyer, W.R., Neglia, J.P., Meadows A., Potter, J.D., Priedman, D., Yasui, Y., Robison, L.L., Davies, S.M. XRCC1 and glutathione-S-transferase gene polymorphisms and susceptibility to radiotherapy-related malignancies in survivors of Hodgkin disease. Cancer. 101:1463-72, 2004.
Perentesis, J.P., Bhatia, S., Boyle, E., Shao, Y., Shu, X.-O., Steinbuch, M., Sather, H. N., Gaynon, P., Kiffmeyer, W.R., Envall-Fox, J., Robison, L.L., Ras oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia. Leukemia, 18(4): 685-92, 2004.
Presentations, Most Recent
"Pediatric Oncology Oral Session Chair" American Society of Oncology's 41st Annual Meeting, Orlando, FL: May 16, 2005.
"Host Pharmacogenetic Factors in the Therapy and Outcome of Childhood Leukemia and Lymphoma," 2005 Shanghai International Pediatric Forum, Shanghai, China: June 17, 2005.
"Targeted Therapies for High Risk Acute Myeloid Leukemia and Acute Lymphoid Leukemia," Children's Hospital of Fudan University, Shanghai, China: June 20, 2005.
"Improving the Outcome in Pediatric Oncology," American Society of Oncology's 42nd Annual Meeting, Atlanta, GA: June 3, 2006.
"Pharmacogenetic Predictors of Toxicity in Dose-Intensive Therapy for Pediatric Advanced-Stage Hodgkin's Lymphoma," American Society of Hematology Annual Meeting, San Diego, CA: December 10, 2006.
Professional Organization Memberships
- Fellow, American Academy of Pediatrics
- American Association for Cancer Research
- American Society for Hematology
- American Society for Clinical Oncology
- American Society of Pediatric Hematology/Oncology
Special Interests
- Acute myeloid laukemia
- Neuroblastoma
- PNET / Ewing's sarcoma and osteosarcomn
- New anticancer drug development
- Phase I clinical trials
Director
